Neurocrine Biosciences, Inc.
NBIXNASDAQHealthcare● Active
$163.12
$-0.76(-0.46%)
Market Cap$16.4B
P/E Ratio—
52W High$169.57
52W Low$122.14
Neurocrine Biosciences, Inc.（NBIX）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NBIX · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.48B | $0.34B | $0.25B | $0.15B | $0.09B |
| Depreciation & Amort. | $0.03B | $0.03B | $0.02B | $0.02B | $0.01B |
| Stock-Based Comp. | $0.22B | $0.20B | $0.19B | $0.17B | $0.13B |
| Change in Working Capital | ($0.13B) | ($0.02B) | $0.03B | ($0.07B) | $0.02B |
| Net Cash from Operations | $0.78B | $0.60B | $0.39B | $0.34B | $0.26B |
| Investing Activities | |||||
| Capital Expenditure | ($0.03B) | ($0.04B) | ($0.03B) | ($0.02B) | ($0.02B) |
| Purchases of Investments | ($1.32B) | ($1.06B) | ($1.41B) | ($0.63B) | ($0.80B) |
| Sales of Investments | $1.09B | $0.97B | $0.97B | $0.51B | $0.70B |
| Net Cash from Investing | ($0.26B) | ($0.13B) | ($0.47B) | ($0.18B) | ($0.13B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.17B) | ($0.30B) | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.31B) | $0.00B | ($0.28B) | ($0.00B) |
| Net Cash from Financing | ($0.04B) | ($0.49B) | $0.07B | ($0.23B) | $0.03B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.75B | $0.56B | $0.36B | $0.32B | $0.23B |
| FCF Margin %(computed) | 26.17% | 23.66% | 19.16% | 21.69% | 20.56% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Neurocrine Biosciences, Inc.
关于Neurocrine Biosciences, Inc.（NBIX）现金流量表
Neurocrine Biosciences, Inc. 2025财年经营活动现金流$0.78B，自由现金流$0.75B（FCF利润率26.17%），资本支出($0.03B)。
常见问题
NBIX · 4 问Neurocrine Biosciences, Inc. 2025财年自由现金流$0.75B，同比up34.4%。
NBIX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10